ARTICLE | Company News
Alexion gains early approval for long-acting PNH therapy
December 21, 2018 11:31 PM UTC
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) received FDA approval for Ultomiris ravulizumab-cwvz (ALXN1210), the biotech's long-acting formulation of Soliris eculizumab, to treat paroxysmal nocturnal hemoglobinuria.
While the approval came nearly two months ahead of the Feb. 18 PDUFA date, Alexion prepared for an early approval scenario and will launch Ultomiris immediately, according to company spokesperson Megan Goulart...
BCIQ Company Profiles